Results 221 to 230 of about 397,641 (267)

Diagnostic and Therapeutic Options in Myocarditis and Inflammatory Cardiomyopathy. [PDF]

Biomedicines
Schultheiss HP, Escher F, Aleshcheva G, Wiegleb G, Baumeier C.   +4 more
europepmc   +1 more source

Lethal ventricular arrhythmia accompanied with myopalladin truncation mutation: a case report. [PDF]

Eur Heart J Case Rep
Yamashita D, Okamoto R, Kagawa Y, Asano Y, Dohi K.   +4 more
europepmc   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel   +12 more
wiley   +1 more source

A Rare Case of Takotsubo Cardiomyopathy Responsive to Fludrocortisone in Secondary Adrenal Insufficiency. [PDF]

Cureus
Khalid W, Khan MU, Khoso M, Zahid N, Latif N, Hassan A.   +5 more
europepmc   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Organelle homeostasis disruption: A driving force in the progression of cardiomyopathy (Review). [PDF]

Exp Ther Med
Hou Y, Li C, Chen Y, Zhong D, Chai M, Mo L, Lin S, Huang F, Chen Q.   +8 more
europepmc   +1 more source

Cardiac remodeling and arrhythmia in a mouse model of Depdc5 haploinsufficiency

Epilepsia, EarlyView.
Abstract Objective Some ion channel genes linked to developmental and epileptic encephalopathy (DEE) are also linked to cardiac arrhythmia, leading to the hypothesis that predisposition to cardiac arrhythmias may contribute to the complex disease presentation of DEE and possibly to the mechanism of sudden unexpected death in epilepsy.
Roberto Ramos‐Mondragon, Shuyun Wang, Qinghua Liu, Chunling Chen, Alexander M. Greiner, Abigail M. Marx, Maya Shih, Jack M. Parent, Barry London, Lori L. Isom   +9 more
wiley   +1 more source

Dystrophin-Deficient Cardiomyopathy Due to a Novel Hemizygous DMD Indel Variant. [PDF]

JACC Case Rep
Albrecht K, Averbuch T, Huculak C, Marcadier J, Oudit G, van Landeghem FKH, Adam B, Lyons KJ, Kiamanesh O.   +8 more
europepmc   +1 more source

Inherited metabolic epilepsies–established diseases, new approaches

Epilepsia Open, EarlyView.
Abstract Inherited metabolic epilepsies (IMEs) represent the inherited metabolic disorders (IMDs) in which epilepsy is a prevailing component, often determining other neurodevelopmental outcomes associated with the disorder. The different metabolic pathways affected by individual IMEs are the basis of their rarity and heterogeneity.
Itay Tokatly Latzer, Phillip L. Pearl
wiley   +1 more source